1. Home
  2. NEUP vs GRNQ Comparison

NEUP vs GRNQ Comparison

Compare NEUP & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEUP
  • GRNQ
  • Stock Information
  • Founded
  • NEUP 1996
  • GRNQ 2013
  • Country
  • NEUP United States
  • GRNQ Malaysia
  • Employees
  • NEUP N/A
  • GRNQ N/A
  • Industry
  • NEUP
  • GRNQ EDP Services
  • Sector
  • NEUP
  • GRNQ Technology
  • Exchange
  • NEUP Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • NEUP 12.7M
  • GRNQ 12.4M
  • IPO Year
  • NEUP N/A
  • GRNQ 2018
  • Fundamental
  • Price
  • NEUP $7.20
  • GRNQ $1.57
  • Analyst Decision
  • NEUP Strong Buy
  • GRNQ
  • Analyst Count
  • NEUP 1
  • GRNQ 0
  • Target Price
  • NEUP $21.00
  • GRNQ N/A
  • AVG Volume (30 Days)
  • NEUP 38.6K
  • GRNQ 50.1K
  • Earning Date
  • NEUP 08-19-2025
  • GRNQ 08-19-2025
  • Dividend Yield
  • NEUP N/A
  • GRNQ N/A
  • EPS Growth
  • NEUP N/A
  • GRNQ N/A
  • EPS
  • NEUP 0.00
  • GRNQ N/A
  • Revenue
  • NEUP $15,662,715.00
  • GRNQ $3,190,761.00
  • Revenue This Year
  • NEUP N/A
  • GRNQ N/A
  • Revenue Next Year
  • NEUP N/A
  • GRNQ N/A
  • P/E Ratio
  • NEUP $4,211.30
  • GRNQ N/A
  • Revenue Growth
  • NEUP N/A
  • GRNQ N/A
  • 52 Week Low
  • NEUP $2.90
  • GRNQ $0.80
  • 52 Week High
  • NEUP $126.00
  • GRNQ $2.50
  • Technical
  • Relative Strength Index (RSI)
  • NEUP N/A
  • GRNQ 38.56
  • Support Level
  • NEUP N/A
  • GRNQ $1.50
  • Resistance Level
  • NEUP N/A
  • GRNQ $1.88
  • Average True Range (ATR)
  • NEUP 0.00
  • GRNQ 0.16
  • MACD
  • NEUP 0.00
  • GRNQ -0.06
  • Stochastic Oscillator
  • NEUP 0.00
  • GRNQ 9.33

About NEUP Neuphoria Therapeutics Inc. Common Stock

Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

Share on Social Networks: